StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$PBH
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare develops, manufactures, markets, sells and distributes over-the-counter health and personal care products for retail and e-commerce customers. It operates through two segments, North American OTC Healthcare and International OTC Healthcare, and sells products in North America, Australia and certain other international markets. Its brands include BC and Goody’s, Chloraseptic, Clear Eyes, Dramamine, Fleet, Gaviscon, Monistat, Summer’s Eve, Fess and Hydralyte, with products spanning pain relief, cough and cold, eye care, gastrointestinal health, dermatology, oral care and women’s health. Prestige sells through mass merchandisers, drug and drug wholesale, food, dollar, convenience and club stores, as well as e-commerce channels. It earns money from sales of its branded products, which it develops and supports through product extensions and marketing, and from brands acquired through acquisitions. Most manufacturing is performed by third-party manufacturers, alongside three company-operated facilities. Prestige is headquartered in Tarrytown, New York.
Prestige Consumer Healthcare (PBH) lowered its full-year Clear Eyes sales forecast to under $20M, citing production issues. Q3 revenue is expected at $328M with EPS of $1.05. Recent acquisitions Breathe Right and LaCorium contributed $71M in H1 revenue. The company plans to prioritize debt reduction, with net debt at $2.1B. E-commerce sales growth continues at a mid-teens rate.
Jefferies reduced its price target for Prestige Brands (PBH) to $51 from $55, citing uncertainty around the Clear Eyes brand's recovery. The stock trades near its 52-week low at $44.32, with a Fair Value estimate of $55.24. Despite strong base business and acquisitions, manufacturing costs and execution risks persist. The firm maintained a Hold rating.
Prestige Consumer Healthcare (PBH) reported Q2 revenue of $336.31M (beating estimates) and adjusted EPS of $1.13. However, it cut fiscal 2027 guidance due to Clear Eyes production issues at the Pillar5 facility. Organic revenue declined 1.6% YoY, and GAAP EPS fell to $0.53. The company cited acquisition-driven growth and ongoing challenges with Clear Eyes.
via TradingView
PBH sentiment & insider activity
Recent PBH coverage spans earnings, corporate actions and financial news.
What's driving PBH
Guidance shortfall and high leverage suggest near-term downside pressure.
AlphAI scores every news story that mentions PBH with an AI model for sentiment and relevance, and aggregates insider trades from Prestige Consumer Healthcare Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Prestige Consumer Healthcare (PBH) lowered its full-year Clear Eyes sales forecast to under $20M, citing production issues. Q3 revenue is expected at $328M with EPS of $1.05. Recent acquisitions Breathe Right and LaCorium contributed $71M in H1 revenue. The company plans to prioritize debt reduction, with net debt at $2.1B. E-commerce sales growth continues at a mid-teens rate.
Jefferies reduced its price target for Prestige Brands (PBH) to $51 from $55, citing uncertainty around the Clear Eyes brand's recovery. The stock trades near its 52-week low at $44.32, with a Fair Value estimate of $55.24. Despite strong base business and acquisitions, manufacturing costs and execution risks persist. The firm maintained a Hold rating.
Prestige Consumer Healthcare (PBH) reported Q2 revenue of $336.31M (beating estimates) and adjusted EPS of $1.13. However, it cut fiscal 2027 guidance due to Clear Eyes production issues at the Pillar5 facility. Organic revenue declined 1.6% YoY, and GAAP EPS fell to $0.53. The company cited acquisition-driven growth and ongoing challenges with Clear Eyes.
Prestige Consumer Healthcare (PBH) reported Q2 Non-GAAP EPS of $1.13, beating estimates by $0.06, with revenue of $336.3M, up 22.7% Y/Y and $7.18M above expectations. The company adjusted its full-year guidance, targeting revenue of $1,280M to $1,290M and Adjusted Diluted EPS of $4.48 to $4.55.
Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results • Q2 Revenue of $336.3 million, up 22.7% versus prior year • Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07 • The Breathe Right
Premium Brands Holdings Corporation (PBH) announced plans for a normal course issuer bid, a move that could support its share price. Details on size, timing, and approvals will determine the impact.
Prestige Consumer Healthcare (PBH) reports the retirement of its Senior Vice President of Operations, Jeffrey Zerillo, effective August 14, 2026. The stock has seen a 14.82% YTD decline but a 7.59% gain over 90 days, with a 1-year return of -22.12%. Analysts suggest PBH is undervalued at $52.15, with a fair value estimate of $66.80, citing strong cash flow and growth prospects, but note risks like supply chain issues and e-commerce competition.
Prestige Brand Holdings is recalling 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to potential contamination. The FDA classified this as a Class II recall, indicating temporary health risks. The affected product has lot code 2552A and expires on September 30, 2027. Prestige Brands' stock (PBH) is up 1.56%.
Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. (the “Company”) of his decision to retire fr
Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.